(Q73393150)
Statements
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis (English)
Braybrooke JP
O'Byrne KJ
Propper DJ
Blann A
Saunders M
Dobbs N
Han C
Woodhull J
Mitchell K
Crew J
Smith K
Stephens R
Ganesan TS
Talbot DC
1 December 2000